Abstract
Background Mepolizumab has been recommended by NICE in 2017 for patients with severe eosinophilic asthma. Aim To investigate the efficacy and tolerability of mepolizumab treatment in severe eosinophilic asthma in a tertiary centre Methods All patients treated with mepolizumab from June 2017 to May 2018 in our centre and completed at least 6 months on treatment were included in this study. We compared baseline clinical outcomes (that included adjusted baseline exacerbation rate to 6 months) and the 6 months on treatment using standard statistics. Results In total, 39 patients were included in the analyses (29 female 74%, mean age=49 years (range 19–75). Comparing baseline to 6 months on treatment, there was significant reduction in the mean rescue oral corticosteroid (OCS) courses from 2.7±0.89 to 1.18±1.37 (p Conclusion This preliminary data showed significant reduction in OCS requiring exacerbations and mean maintenance prednisolone treatment following 6 months of mepolizumab treatment in patients with severe eosinophilic asthma. The treatment was generally well tolerated. The 12 months outcomes data will be available for presentation in the conference.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
